Search research articles
Contact Us
Filters
Showing results (71-80 of 136) with videos related to
Page
of 14
Sort By:
The Oncologist
|
February 3, 2019
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma
Daniel Reinhorn, Michal Sarfaty, Moshe Leshno, et al.
Nature Biotechnology
|
December 9, 2021
Combination therapy patents: a new front in evergreening
Garth W Strohbehn, Alec J Kacew, Daniel A Goldstein, et al.
Clinical Pharmacology and Therapeutics
|
April 17, 2020
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value
Anthony V Serritella, Garth W Strohbehn, Daniel A Goldstein, et al.
BMJ Oncology
|
January 31, 2025
Choosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancer
Daniel A Goldstein, Roi Tschernichovsky, Talish Razi, et al.
The Annals of Pharmacotherapy
|
June 17, 2016
Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab
Christine C Davis, Amelia Zelnak, J William Eley, et al.
British Journal of Cancer
|
August 4, 2023
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
Austin Wesevich, Daniel A Goldstein, Koosha Paydary, et al.
Clinical Colorectal Cancer
|
July 1, 2019
The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States
Assaf Moore, Robert B Den, Noa Gordon, et al.
Leukemia & Lymphoma
|
October 26, 2017
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma
Qiushi Chen, Ashley D Staton, Turgay Ayer, et al.
Cancer Medicine
|
May 7, 2020
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer
Daniel A Goldstein, Chen Mayer, Tzippy Shochat, et al.
Health Economics
|
December 28, 2020
Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19
Andrew H Briggs, Daniel A Goldstein, Erin Kirwin, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 136) with videos related to
Sort By:
Page
of 14
The Oncologist
|
February 3, 2019
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma
Daniel Reinhorn, Michal Sarfaty, Moshe Leshno, et al.
Nature Biotechnology
|
December 9, 2021
Combination therapy patents: a new front in evergreening
Garth W Strohbehn, Alec J Kacew, Daniel A Goldstein, et al.
Clinical Pharmacology and Therapeutics
|
April 17, 2020
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value
Anthony V Serritella, Garth W Strohbehn, Daniel A Goldstein, et al.
BMJ Oncology
|
January 31, 2025
Choosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancer
Daniel A Goldstein, Roi Tschernichovsky, Talish Razi, et al.
The Annals of Pharmacotherapy
|
June 17, 2016
Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab
Christine C Davis, Amelia Zelnak, J William Eley, et al.
British Journal of Cancer
|
August 4, 2023
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
Austin Wesevich, Daniel A Goldstein, Koosha Paydary, et al.
Clinical Colorectal Cancer
|
July 1, 2019
The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States
Assaf Moore, Robert B Den, Noa Gordon, et al.
Leukemia & Lymphoma
|
October 26, 2017
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma
Qiushi Chen, Ashley D Staton, Turgay Ayer, et al.
Cancer Medicine
|
May 7, 2020
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer
Daniel A Goldstein, Chen Mayer, Tzippy Shochat, et al.
Health Economics
|
December 28, 2020
Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19
Andrew H Briggs, Daniel A Goldstein, Erin Kirwin, et al.
Page
of 14